AfricaRegulatory
African Pharmaceutical Regulatory Intelligence
RECOMBINANT HUMAN ERYTHROPOIETIN
8 registrations across 5 African markets— 8 active
Markets with RECOMBINANT HUMAN ERYTHROPOIETIN
Recent registrations
| Brand / Product | Market | Holder | Status | Expires |
|---|---|---|---|---|
| EPOFIT 4000IU INJECTION USP | 🇷🇼Rwanda | Intas Pharmaceutical Ltd. | active | Mar 2031 |
| INJ. EPOFIT -2000i.u Injection | 🇰🇪Kenya | Intas Pharmaceuticals Ltd | active | Sept 2030 |
| INJ. EPOFIT -4000i.u Injection | 🇰🇪Kenya | Intas Pharmaceuticals Ltd | active | Sept 2030 |
| REPOITIN | 🇬🇭Ghana | — | active | Mar 2030 |
| REPOITIN | 🇬🇭Ghana | — | active | Mar 2030 |
| Foligraf 150 Injection | 🇹🇿Tanzania | Bharat Serums and Vaccines Limited | active | — |
| RECOMBINANT
HUMAN
ERYTHROPOIETIN PARENTERAL
ORDINARY PRE-
FILLED SYRINGES | 🇺🇬Uganda | WOCKHARDT LTD | active | — |
| RECOMBINANT
HUMAN
ERYTHROPOIETIN PARENTERAL
ORDINARY PRE-
FILLED SYRINGES | 🇺🇬Uganda | WOCKHARDT LTD | active | — |
RECOMBINANT HUMAN ERYTHROPOIETIN in Africa — Regulatory Overview
RECOMBINANT HUMAN ERYTHROPOIETIN is registered across 5 African markets with 8 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including Ghana, Kenya, Uganda, Rwanda and 1 more. AfricaRegulatory refreshes this data daily from official government sources.
Of the 8 registrations, 8 (100%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.